HAMAD GENERAL HOSPITAL
- Country
- 🇶🇦Qatar
- Ownership
- -
- Established
- 1982-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Integrated Life Skill Training and Executive Function Strategies in Children With ASD
- Conditions
- Autism Spectrum Disorder
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Hamad General Hospital
- Target Recruit Count
- 92
- Registration Number
- NCT05829577
- Locations
- 🇶🇦
Hamad Medical Corporation, Doha, Qatar -doha, Qatar
Efficacy of Extracorporeal Magnetic Stimulation, Pelvic Floor Muscle Exercise, and Combination of Both in Management of Post Radical Prostatectomy Urinary Incontinence
- Conditions
- Post Radical Prostatectomy Urinary Incontinence
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Hamad General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05680168
- Locations
- 🇶🇦
Ambulatory Care Center, Doha, Qatar
To Assess Use of Vancomycin Powder in Craniotomy on Wound Infection Rates
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Hamad General Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT04917627
- Locations
- 🇶🇦
Hamad General Hospital, Doha, Qatar
News
First-Ever RCT to Evaluate Human Albumin's Effectiveness in Aneurysmal Subarachnoid Hemorrhage Launches in Qatar
• Hamad General Hospital in Qatar initiates groundbreaking randomized controlled trial to assess human albumin's impact on clinical outcomes in aneurysmal subarachnoid hemorrhage patients. • The three-year study will enroll 84 patients to compare albumin-enhanced fluid management versus standard crystalloid therapy, focusing on reducing cerebral vasospasm and improving neurological outcomes. • The trial addresses a critical research gap, as aneurysmal subarachnoid hemorrhage affects working-age populations with up to 60% mortality rate in untreated cases.